Related Experiment Video

Updated: Jun 9, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Novel regulators and drug targets of cardiac hypertrophy

Piet Finckenberg1, Eero Mervaala

  • 1Institute of Biomedicine, University of Helsinki, Finland.

Journal of Hypertension
|September 9, 2010
PubMed

Insights

Cardiac hypertrophy, an adaptive response, can become pathological, leading to heart failure. Novel regulators and drug targets are being identified through advanced research, offering new therapeutic avenues.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Systems Biology

Background:

  • Cardiac hypertrophy is a complex response to stress, potentially progressing to heart failure.
  • Understanding its molecular mechanisms is crucial for developing effective treatments.
  • Distinct metabolic alterations occur in hypertrophy and heart failure.

Purpose of the Study:

  • To review current knowledge on molecular mechanisms of cardiac hypertrophy.
  • To highlight novel regulators and potential drug targets.
  • To explore the role of systems biology in biomarker discovery.

Main Methods:

  • Review of current literature on cardiac hypertrophy.
  • Analysis of gene-modified and acquired models.
  • Focus on systems biology approaches like metabolomics.

Main Results:

  • Identified key triggers of pathological cardiac hypertrophy: biomechanical stress and neurohumoral activation.
  • Highlighted novel regulators: tissue renin-angiotensin-aldosterone system, calcineurin/NFAT, PI3K/Akt, mTOR, HDACs, AMPkinases, microRNAs, and angiogenetic factors.
  • Emphasized distinct cardiac substrate utilization patterns in hypertrophy and heart failure.

Conclusions:

  • Novel regulators and drug targets offer therapeutic potential for cardiac hypertrophy.
  • Systems biology, particularly metabolomics, can provide insights into metabolic processes and aid biomarker discovery.
  • Further research into these pathways is essential for advancing cardiovascular disease treatment.

More Related Videos

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...